Company intelligence / Profile preview
CardioPharma
Wilmington, North Carolina, United Statescardio-pharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CardioPharma is developing fixed-dose combination oral therapies for cardiovascular disease. Its lead product, CardiaPill®, combines a statin, an ACE inhibitor, and an anti-platelet agent to improve patient adherence and outcomes. The company has secured global patents for its formulations but has not yet reported late-stage clinical results or commercial launches[2][6].
- Therapeutic areas
- Cardiovascular
- Modalities
- Small moleculeCombination therapy (fixed-dose combination)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Patents licensed from Harvard’s Brigham and Women’s Hospital and Massachusetts College of Pharmacy[2]. No major pharma partnerships disclosed.
Beyond the preview
Go deeper on CardioPharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CardioPharma.